MaxCyte (NASDAQ:MXCT) reported quarterly losses of $(0.09) per share which met the analyst consensus estimate. This is a 10 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $7.300 million which missed the analyst consensus estimate of $9.398 million by 22.33 percent. This is a 16.02 percent decrease over sales of $8.693 million the same period last year.